Boston BioProducts (BBP) has been creating buffers that advance scientific discovery for over 29 years. By building strong working relationships to understand individual customer needs, BBP delivers customizable buffers¹ that scientists can rely on.

BBP provides buffers for a range of applications, and this case study explores how their ongoing partnership with Duke Human Vaccine Institute² (DHVI) facilitated rapid progress in HIV, Flu, and COVID-19 vaccine development.